MELBOURNE: Starpharma Holdings has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA.

Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP technology.

Dr Jackie Fairley, CEO of Starpharma commented: “MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area.”

DEP ADCs exploit the unique potential of Starpharma’s DEP® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches.

DEP ADCs are the subject of internal and partnered programs. Starpharma has previously demonstrated the significant advantages conveyed by DEP ADCs in multiple preclinical studies, including its DEP HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcylain a human ovarian cancer model.

Starpharma’s DEP technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.

Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers.  www.starpharma.com